Whether EMV-derived TGF-β increases MDSC-mediated osteoclastic resorption in the OS BME is currently unknown and is the subject of our future studies. Blocking exosome-derived TGF-β is an attractive therapeutic strategy to reduce osteoclastic activity from MDSCs in the tumor microenvironment and increase the efficacy of antitumor immune therapies. Detection of CD-9, a tetraspanin
protein http://www.selleckchem.com/products/SP600125.html in the EMVs derived from 143B cells, is a novel finding. To our best knowledge, the role of this protein in osteosarcoma pathobiology has never been investigated. Besides being a designated exosome-specific marker, CD-9 is also a pro-osteoclastogenic fusogenic protein as it regulates osteoclast differentiation and the formation of mature polykaryons [36] and [59]. It is overexpressed in osteotropic cancers and not only promotes the homing of cancer cells in the bone marrow but also induces osteoclastic bone resorption [37]. Studies report that inhibition of CD-9 by KMC8, a widely used antibody against CD-9, suppresses osteoclastogenesis [60], whereas RANKL-stimulated expression of CD-9 and other fusogenic genes such as CD-47 in osteoclast precursors promotes mature polykaryotic, tartarate-resistant acid phosphatase and osteoclast-specific
Selleck BMN673 transmembrane protein expressing osteoclast phenotype [61]. A recent study demonstrated the role of CD-9 in mediating MMP-9–induced migration and invasion in fibrosarcoma
cells [62]. Elevation of intracellular calcium concentration on forskolin pretreatment and ionomycin sensitization of 143B cells leads to changes in the cytoskeleton architecture and vesicle biogenesis. This finding is important especially in the context the of osteosarcoma BME where actively metabolizing cancer cells maintain energy homeostasis by regulating cytosolic calcium through induction of oscillatory events that eventually trigger cytoskeleton rearrangements and vesicle biogenesis. Previous studies have reported that elevated intracellular calcium concentration [Ca++]i, cAMP levels, and P2X7 receptor (purinergic receptor ion channels mediating calcium and influx across the plasma membrane) activation modulate the pool of EMV output and sorting of cargo by regulating docking, priming, and exocytosis of vesicles [19], [63] and [64]. Identification of targets associated with EMV biogenesis in response to elevated calcium or adenylate cyclase remains to be elucidated. Therapies targeting the osteosarcoma BME could be designed to either inhibit EMV biogenesis directly or inactivate their bone-destructive, proneoplastic cargo. In conclusion, this study suggests a novel role of EMVs in driving osteoclastic bone resorption by virtue of their pro-osteoclastogenic cargo and disrupting bone remodeling homeostasis in the osteosarcoma BME. Figure W1.